Skip to main content

Table 3 Changes in efficacy variables from baseline to 24 months for those remaining on the chosen treatment (n = 726)

From: A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy

 

Met/Incr

Met/SU

p-value* vs. Met/Incr

Insulin ± any OAD

p-value* vs. Met/Incr

(n = 421)

(n = 154)

(n = 151)

HbA1c (%)

     

 BL mean ± SD

7.4 ± 1.1

7.5 ± 1.4

 

8.6 ± 1.7

 

 Mean change vs. BL ± SD

−0.5 ± 1.0

−0.6 ± 1.4

0.039

−0.9 ± 2.0

0.003

FPG (mg/dl)

     

 BL mean ± SD

142 ± 41

143 ± 43

 

173 ± 66

 

 Mean change vs. BL ± SD

−19 ± 42

−15 ± 41

0.34

−24 ± 70

0.001

PPG (mg/dl)

     

 BL mean ± SD

201 ± 243

189 ± 52

 

224 ± 130

 

 Mean change vs. BL ± SD

27 ± 463

60 ± 330

0.61

90 ± 535

0.066

Body weight (kg)

     

 BL mean ± SD

91.2 ± 17.9

88.1 ± 14.8

 

93.7 ± 19.6

 

 Mean change vs. BL ± SD

−1.5 ± 5.0

−0.4 ± 4.8

0.17

0.8 ± 9.0

0.028

  1. Legend: BL, baseline; Met/Incr, metformin/incretin; Met/SU, metformin/sulfonylurea; OAD, oral antidiabetic drug; HbA1c, glycosylated haemoglobin A1c, FPG, fasting plasma glucose; PPG, postprandial plasma glucose; SD, standard deviation. *Adjusted for differences in baseline characteristics: age, sex, body weight, diabetes duration, heart failure, coronary artery disease, HbA1c, FPG, and PPG.